Last updated 2026-06-18
- Raised funding round, Sep 2022
Total raised
—
Last: 2022-09
Stage
Seed
Founded
2022
Headcount
6
HQ
Or Yehuda, Israel
Sector
Health Tech & Life Sciences
About
NovaPulse is a bioconvergence company specializing in the multibillion-dollar peripheral artery disease market. The company is focused on helping the millions of claudication patients who suffer from pain and have trouble walking because of insufficient blood supply to their legs.
NovaPulse is the brainchild of the MEDX Xelerator incubator.
Funding history · 1 round · — total
2022-09
Undisclosed
Q&A
- What is NovaPulse's primary focus?
- NovaPulse is a bioconvergence company specializing in the peripheral artery disease market, aiming to help claudication patients suffering from pain and walking difficulties due to insufficient blood supply to their legs.
- When was NovaPulse founded?
- NovaPulse was founded in January 2022.
- Where is NovaPulse headquartered?
- NovaPulse is headquartered in Or Yehuda, Israel.
- What is NovaPulse's current product stage?
- NovaPulse's product is currently in the clinical trial stage.
- Which investors participated in NovaPulse's funding round in September 2022?
- In September 2022, Almeda Ventures and MEDX Xelerator invested in NovaPulse.
- What is NovaPulse's primary sector?
- NovaPulse's primary sector is Health Tech & Life Sciences.
- What business models does NovaPulse employ?
- NovaPulse utilizes both B2C and B2B business models.
Team · 1
Founder · founders
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2CB2B
Tags
bioconvergencecardiologyheart-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2022-1 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 2 |
|---|